Phase III QUAZAR AML-001 study meets OS endpoint

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase III study on CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia found statistically significant and clinically meaningful improvement in overall survival compared to placebo.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login